1[18]Stass HH, Muller F, Hundt HK, et al. Study of the influence of once-daily 400 mg moxifloxacin on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. [C]. 38(th) Intersci Conf Antimicrob Agents Chemother, Sept 24-2 7, San Diego, 1998, Abst A13
2[19]Stass HH, Kubitza D, Schwietert H, et al. Bay12-8039 does not interact with t heophylline. [C]. 20(th) Int Cong Chemother, June 29-July 3, Sydney, 1997, Abst3 356
3[20]Krasemann C, Meyer JM, Springsklee M. Moxifloxacin (MFX) in community-acquired pneumonia (CAP)-A bacteriologic and clinical meta-analysis. [J]. Clin Microbiol Infect, 1999,5(Suppl 3): Abst 205
4[21]Petipretz P. Moxifloxacin(MFX) versus amoxycillin(AMOX) in the treatment of community -acqnired suspected pneumococcal pneumonia: A mutinational double -blind randonized study. [J]. Clin Microbiol Infect, 1999,5(Suppl 3):Abst 207
5[22]Wilson R,Kubin R,Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute cxacerbations of chronic bronchitis. [J]. J Antimicrob Chemother, 1999,44(4): 501
6[23]Krasemann C, Meyer JM, Springsklee M. Moxifloxacin(MFX) in acute sinusiti s (A S) - A bacteriologic and clinical meta-analysis. [J]. Clin Microbiol Infect, 1999,5(Suppl 3):Abst P204
7[24]Leal del Rosal P. Efficacy and safety of moxifloxacin vs cephalexin in the treatment of mild to moderate uncomplicated skin and soft tissue infections (USS SI). [J]. J Antimicrob Chemother, 1999,44(Suppl A): Abst 493
8[1]Hoogkamp-Korstanje JAA, Roelofs - Willemse J. Comparative in vitro activity of moxifloxacin against Gram - positive clinical isolates. [J]. J Antimicrob Chemother, 2000,45(1):31
9[2]Blondeau JM. A review of the comparative in - vitro activities of 12 antimicrobial agents, with a focus on five new " respiratory qninolones". [J]. J Antimicrob Chemother, 1999,43 (SupplB): 1
10[3]Boswell FJ, Andrews JM, Wise R, et al. Bactericidal properties of moxifloxacinand post-antibiotic effect. [J]. J Antimicrob Chemother, 1999,43(Suppl B):43
